Aura Biosciences Q1 2025 Update
Ticker: AURA · Form: 10-Q · Filed: 2025-05-15T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, biotechnology, financials, agreements
TL;DR
Aura Biosciences Q1 2025 10-Q filed. Financials and key agreements detailed.
AI Summary
Aura Biosciences, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial condition, including its cash and cash equivalents and its net loss for the three months ended March 31, 2025. The filing also details various agreements, including a Collaboration Research and Development Agreement and an Exclusive License and Supply Agreement with LICOR Inc. The company's principal executive offices are located at 80 Guest Street, Boston, MA.
Why It Matters
This filing provides insight into Aura Biosciences' financial health and ongoing operational activities, which are crucial for investors and stakeholders to assess the company's progress and future prospects.
Risk Assessment
Risk Level: medium — As a biotechnology company, Aura Biosciences faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 20250331 — Reporting Period End Date (Indicates the end of the financial quarter being reported.)
- 001-40971 — SEC File Number (Unique identifier for the company's SEC filings.)
Key Players & Entities
- Aura Biosciences, Inc. (company) — Filer
- March 31, 2025 (date) — Reporting period end date
- 80 Guest Street, Boston, MA (location) — Company address
- LICOR Inc. (company) — Party to agreements
- Dr. John Schiller (person) — Mentioned in relation to an agreement
FAQ
What was Aura Biosciences' net loss for the three months ended March 31, 2025?
The filing does not explicitly state the net loss amount for the three months ended March 31, 2025, but it indicates that financial results for this period are being reported.
What is the nature of the Exclusive License and Supply Agreement with LICOR Inc.?
The filing mentions an Exclusive License and Supply Agreement with LICOR Inc., but the specific terms and purpose are not detailed in the provided header information.
When was the Collaboration Research and Development Agreement entered into?
The filing references a Collaboration Research and Development Agreement, but the specific date of entry is not provided in the header.
What is the company's fiscal year end?
Aura Biosciences' fiscal year ends on December 31.
What is the company's SIC code and industry classification?
The company's SIC code is 2836, and it is classified under BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
From the Filing
0000950170-25-071907.txt : 20250515 0000950170-25-071907.hdr.sgml : 20250515 20250515060514 ACCESSION NUMBER: 0000950170-25-071907 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 75 CONFORMED PERIOD OF REPORT: 20250331 FILED AS OF DATE: 20250515 DATE AS OF CHANGE: 20250515 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aura Biosciences, Inc. CENTRAL INDEX KEY: 0001501796 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 320271970 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-40971 FILM NUMBER: 25948359 BUSINESS ADDRESS: STREET 1: 80 GUEST STREET CITY: BOSTON STATE: MA ZIP: 02135 BUSINESS PHONE: (617)500-8864 MAIL ADDRESS: STREET 1: 80 GUEST STREET CITY: BOSTON STATE: MA ZIP: 02135 10-Q 1 aura-20250331.htm 10-Q 10-Q false 0001501796 Q1 --12-31 http://fasb.org/srt/2024#ChiefExecutiveOfficerMember 0001501796 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001501796 aura:CollaborationResearchAndDevelopmentAgreementMember aura:DrJohnSchillerMember aura:TenAnniversaryMember 2024-09-01 2024-09-30 0001501796 aura:LICORIncMember aura:ExclusiveLicenseAndSupplyAgreementMember 2025-01-01 2025-03-31 0001501796 aura:LICORIncMember aura:ExclusiveLicenseAndSupplyAgreementMember 2014-01-01 2014-01-31 0001501796 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001501796 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001501796 aura:TwoThousandTwentyOneStockOptionAndIncentivePlanMember 2025-03-31 0001501796 aura:OfficeAndLaboratoryFacilityMember 2025-01-01 2025-03-31 0001501796 aura:TwoThousandTwentyOneStockOptionAndIncentivePlanMember 2025-01-01 0001501796 aura:CommonStockWarrantsMember aura:SeriesBWarrantsMember 2021-11-02 0001501796 us-gaap:GeneralAndAdministrativeExpenseMember 2025-01-01 2025-03-31 0001501796 us-gaap:AssetUnderConstructionMember 2025-03-31 0001501796 aura:FourZeroOneKPlanMember 2024-01-01 2024-03-31 0001501796 aura:TwoThousandTwentyOneEmployeeStockPurchasePlanMember 2021-01-01 0001501796 aura:NonExclusiveLicenseAgreementMember srt:MaximumMember aura:RakutenMember 2014-12-31 0001501796 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-03-31 0001501796 aura:LICORIncMember aura:ExclusiveLicenseAndSupplyAgreementMember 2024-01-01 2024-03-31 0001501796 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001501796 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001501796 aura:CollaborationResearchAndDevelopmentAgreementMember aura:DrJohnSchillerMember 2024-01-01 2024-03-31 0001501796 aura:ClinicalPreclinicalAndResearchAndDevelopmentOperationsMember 2025-01-01 2025-03-31 0001501796 aura:RoyaltyBearingPatentLicenseAgreementMember 2009-11-01 2009-11-30 0001501796 aura:LabEquipmentMember 2025-03-31 0001501796 aura:OfficeAndLaboratoryFacilityMember 2025-03-31 0001501796 aura:NonExclusiveLicenseAgreementMember aura:DrJohnSchillerMember 2024-09-01 2024-09-30 0001501796 aura:ChemistryManufacturingAndControlsMember 2024-01-01 2024-03-31 0001501796 us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001501796 us-gaap:CommonStockMember 2023-12-31 0001501796 2025-05-09 0001501796 aura:AtTheMarketOfferingMember 2023-01-01 2023-12-31 0001501796 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001501796 us-gaap:RestrictedStockUnitsRSUMember 2024-12-31 0001501796 aura:NationalInstituteOfHealthMember 2025-01-01 2025-03-31 0001501796 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001501796 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0001501796 aura:CommonStockWarrantsMember aura:SeriesBWarrantsMember 2025-03-31 0001501796 aura:FourZeroOneKPlanMember 2025-01-01 2025-03-31 0001501796 us-gaap:CommonStockMember aura:TwoZeroTwoThreeFollowOnOfferingMember 2023-11-09 0001501796 2025-01-01 2025-03-31 0001501796 us-gaap:AccumulatedOtherCom